On Monday shares of Myriad Genetics (NASDAQ: MYGN) declined on concerns about medical reimbursement. In the view of Leerink Swann, the published reimbursement rate for BRCA1 & BRCA2 was an error, and the stock is likely to recover losses. “MYGN’s stock sold-off late in yesterday’s trading session on concerns that the company’s Medicare administrative contractor (MAC) Noridian slashed reimbursement for BRCA1 & BRCA2 full sequence (i.e., CPT code 81211) by ~48%.
Help employers find you! Check out all the jobs and post your resume.
